研究業績

研究論文

著書

1. 麻生好正：ガイドラインにないリアル糖尿病薬物治療をガイドする. 9. ASCVD合併2型糖尿病, pp63-71, 坂根直樹編, 新興医学出版社,東京, 2022年
2. 麻生好正：患者さんに合わせた糖尿病治療ができる～血糖管理と薬剤選択の大原則～.第1章8. 神経障害を訴える患者への処方は? pp62-69, 坂根直樹編,　羊土社, 東京, 2022年
3. 薄井勲：第9章　肥満症に合併する疾患の疫学・成因・予防・治療. 140-143, 肥満症診療ガイドライン 2022, 編集 日本肥満学会,2022

総論

1. 麻生好正：特集2022年（ことし）なにがあった?　TOPICS糖尿病の新規治療薬イメグリミン！その作用とは?　薬局2022;73：62-66
2. 麻生好正.　特集2　糖尿病性自律神経障害　～実は、その症状は自律神経障害かも？～.さかえ2023；63：33-38.
3. 飯嶋　寿江：腎臓症候群（第3版）　Ⅲ　―その他の腎臓疾患を含めてー Ⅸ 各種病態にみられる腎障害　甲状腺疾患　pp22-25,別冊日本臨床 領域別症候群シリーズ No.24　2022年

Original

1. Shinohara Y, Ando H, Maekawa M, Arai M, Horibata Y, Satou M, Jojima T, Usui I, Aso Y, Sugimoto H. Transcription of cytochrome P450 46A1 in NIH3T3 cells is negatively regulated by FBS. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Mar 16;1867(6):159136.
2. Hirao N, Iijima T, Tanuma D, Ohira E, Kurai H, Shinzawa T, Kase M, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. 'Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein-1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease. Clin Endocrinol (Oxf) (in press)
3. Jojima T, Kurai H, Tanuma D, Kajitani H, Kase M, Inoue Y, Sakurai S, Iijima T, Tomaru T, Usui I, Aso Y. Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes. Int J Cardiol Heart Vasc. 2022 Jun 16;41:101071
4. Shibasaki I, Nakajima T, Fukuda T, Hasegawa T, Ogawa H, Tsuchiya G, Takei Y, Tezuka M, Kato T, Kanazawa Y, Kano Y, Kuwata T, Ouchi M, Toyoda S, Aso Y, Fukuda H. Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors. J Clin Med. 2022 Jul 26;11(15):4333.
5. Kase M, Iijima T, Niitani T, Sagara M, Sakurai S, Tomaru T, Jojima T, Usui I, and Aso Y. Relationship Between Reduced Heart Rate Variability and Increased Arterial Stiffness Evaluated by the Cardio-Ankle Vascular Index in People With Type 2 Diabetes. Diabetol Int 2022 Sep 29;14(1):94-102
6. Kishi H, Usui I, Jojima T, Fujisaka S, Wakamatsu S, Mizunuma-Inoue Y, Niitani T, Sakurai S, Iijima T, Tomaru T, Tobe K, Aso Y. Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed Mice. Int J Mol Sci. 2022 Dec 4;23(23):15309.
7. Ken-Ichi Inoue, Hidetsugu Yamagishi , Teruo Jojima, Teruo Inoue, Shigeru Toyoda Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet. ANTICANCER RESEARCH.2022; 42: 609-617

Review

• Common metabolic features of hypertension and type 2 diabetes. Isao Usui. Hypertension Research 2023 (in press)

Case reports

1. Shinzawa T, Usui I, Hanawa K, Kajitani H, Sakurai S, Tomaru T, Iijima T, Jojima T, Kojima K, Aso Y. Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity. Intern Med. 2022 Sep 1;61(17):2631-2635.
2. Jojima T, Shinzawa T, Ohira E, Sakurai S, Tomaru T, Iijima T, Kogai T, Usui I, Aso Y. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. Endocr J. 2022 Aug 29;69(8):941-945.

Editorial

• Hypertension and insulin resistance in adipose tissue. Isao Usui. Hypertension Research 2023 (in press)

学会

1. 麻生好正.　シンポジウム23.　糖尿病性自律神経障害Update.　第65回日本糖尿病学会年次学術集会、2022年5月、神戸
   麻生好正.　シンポジウム3.　糖尿病性自律神経障害の診断と治療. 第37回日本糖尿病合併症学会、2022年10月、京都
   麻生好正.　教育講演：神経症状を訴える患者への療養指導.　第57回糖尿病学の進歩、　2023年2月、東京
2. 薄井勲、城島輝雄、角朝信、瀧川章子、若松翔、藤坂志帆、戸邉一之、麻生好正：高脂肪食による癌の発症と増殖促進作用。第64回日本糖尿病学会年次学術集会、Web、2021.5.

研究論文

著書

1. 麻生好正. 2型糖尿病. 今日の治療指針2022, 福井次男・高木誠・小室一成　編, pp738-745,　医学書院, 東京, 2022.1.1.
2. 麻生好正. IX糖尿病性神経障害. 3.自律神経障害. 糖尿病最新の治療2022-2024, 荒木栄一・綿田裕孝・山内敏正 編, pp223-226, 南江堂, 東京, 2021.11.15.

Original

1. Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T, Kogai T, Usui I, and Aso Y. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patient with type 2 diabetes: an association with a mild increase in high-density lipoprotein (HDL) cholesterol. Int J Cardiol 2021 May 15;331:243-248
2. Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, and Aso Y. Serum Levels of Soluble Dipeptidyl Peptidase-4 in Type 2 Diabetes are Associated With Severity of Liver Fibrosis Evaluated by Transient Elastography (FibroScan) and the FAST (FibroScan-AST) Score, a Novel Index of Non-Alcoholic Steatohepatitis With Significant Fibrosis. J Diabetes Complications 2021 May;35(5):107885.
3. Aso Y, Sagara M, Niitani T, Kato K, Iijima T, Tomaru T, Jojima T, and Usui I. Serum high-molecular weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Invest Med 2021 Oct;69(7):1324-1329.
4. Ijima T, Hosonuma S, Kurai H, Kajitani H, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Acute effect of add-on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24-hour glucose profile and glycemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors. Int J Clin Pract 2021 Nov;75(11):e14732.
5. Katano-Toki A, Yoshino S, Nakajima Y, Tomaru T, Nishikido A, Ishida E, Horiguchi K, Saito T, Ozawa A, Satoh T, Yamada M. SFPQ associated with a co-activator for PPARg, HELZ2, regulates key nuclear factors for adipocyte differentiation. BBRC. 2021 Jul 562;139-145.

Case reports

1. Sakurai S, Hosonuma S, Iijima T, Tomaru T, Jojima T, Usui I, and Aso Y. A case of hyperglycemic hyperosmolar state with hyponatremia and subsequent gastrointestinal bleeding due to acute gastric mucosal lesions. Dokkyo J Med Sci 2021; 48:97-101
2. Shinzawa T, Usui I, Hanawa K, Kajitani H, Sakurai S, Tomaru T, Iijima T, Jojima T, Kojima K, Aso Y. Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity. Intern Med. 2022 Feb 8. doi: 10.2169/internalmedicine.8446-21.
3. Iijima T, Jojima T, Hosonuma S, Ohhira E, Tomaru T, Kogai T, Usui I, Aso Y. Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomy. Endocr J. 2021 Oct 28;68(10):1187-1195. doi: 10.1507/endocrj.EJ20-0717.

Review

英文

• Aso Y. Updates in diabetic neuropathy: A call for new diagnostic and treatment approaches. J Diabetes Investig. 2022 Mar;13(3):432-434.

和文

1. 麻生好正、加瀬正人.　糖尿病性自律神経障害の特徴と対策～心血管自律神経障害を中心に～. 糖尿病合併症 2021; 35: 270-275
2. 加瀬正人、麻生好正.　糖尿病診療における臨床検査. IV合併症検査 2. 神経障害. 月刊糖尿病 2021; 13: 70-78
3. 麻生好正.　経口血糖降下薬の温故知新. 6. DPP-4阻害薬.　月刊糖尿病　2021; 13: 38-46
4. 麻生好正.　かかりつけ医からみた糖尿病診療. 急性合併症.　診断と治療 2022; 110: 337-344
5. 登丸琢也．①知っておきたい甲状腺機能異常症の最近の話題　免疫チェックポイント阻害薬による甲状腺機能異常と治療．Medical Practice 39(1); 49-53, 2022.

Letter

• Aso Y, Iijima T, Tomaru T, Jojima T, and Usui I. No negative impact of a national state of emergency by covid-19 outbreak on hemoglobin A1c levels in Japanese people with type 2 diabetes living in a semi-rural area of Japan. Am J Med Sci 2021 Jul;362(1):104-105.

Commentary

• Aso Y. Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes in the ACCORD Trial: a post-hoc analysis. J Diabetes Invest 2021 Aug;12(8):1316-1318

学会

1. 麻生好正、加瀬正人.　シンポジウム30 糖尿病神経障害の新しい展開. 糖尿病性心血管自律神経障害の診断・治療の新展開. 第64回日本糖尿病年次学術集会. WEB, 2021.5
2. 麻生好正.　シンポジウム1 眼科の先生に知っていただきたい最近の糖尿病治療のトピックス. 糖尿病治療のゲームチェンジャーとなったSGLT2阻害薬とGLP-1受容体作動薬. 第27回日本糖尿病眼学会総会. WEB, 2021.10

研究論文

著書

1. 麻生好正.　I.症候編1.全身にみられる徴候. 高血糖. 今日の診断指針第8版，永井良三編，pp99-103, 医学書院，東京，2020.
2. 麻生好正．糖尿病専門医研修ガイドブック改訂第8版：第11章　合併症ならびに併発症．糖尿病性神経障害．日本糖尿病学会編，pp323-326、診断と治療社，東京，2020.

原著

1. Aso Y, Takada Y, Tomotsune K, Chiba Y, Matsumura M, Jojima T, Sato M, Fujita N, Kuroda H, Murano S, Usui I.Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial. Int J Clin Pract. 2021 Apr;75(4):e13734.
2. Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis. J Diabetes Complications. 2020 Nov;34(11):107703.
3. Aso Y, Kase M, Sagara M, Sakurai S, Iijima T, Tomaru T, Jojima T, Usui I.Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes. Am J Med Sci. 2020 Sep;360(3):261-267.
4. Mizunuma Y, Kanasaki K, Nitta K, Nakamura Y, Ishigaki Y, Takagaki Y, Kitada M, Li S, Liu H, Li J, Usui I, Aso Y, Koya D.CD-1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis. J Diabetes Investig. 2020 Nov;11(6):1470-1481.
5. Inoue KI, Toyoda S, Jojima T, Abe S, Sakuma M, Inoue T. Time-restricted feeding prevents high-fat and high-cholesterol diet-induced obesity but fails to ameliorate atherosclerosis in apolipoprotein E-knockout mice. Exp Anim. 2020 Dec 3. doi: 10.1538/expanim.20-0112.
6. Okabe K, Nawaz A, Nishida Y, Yaku K, Usui I, Tobe K, Nakagawa T. NAD+ Metabolism Regulates Preadipocyte Differentiation by Enhancing α-Ketoglutarate- Mediated Histone H3K9 Demethylation at the PPARγ Promoter. Front Cell Dev Biol. 2020; 8: 586179.
7. Fujisaka S, Usui I, Nawaz A, Igarashi Y, Okabe K, Furusawa Y, Watanabe S, Yamamoto S, Sasahara M, Watanabe Y, Nagai Y, Yagi K, Nakagawa T, Tobe K. Bofutsushosan improves gut barrier function with a bloom of Akkermansia muciniphila and improves glucose metabolism in mice with diet-induced obesity. Sci Rep. 2020 Mar 26;10(1):5544.
8. Nishida Y, Nawaz A, Kado T, Takikawa A, Igarashi Y, Onogi Y, Wada T, Sasaoka T, Yamamoto S, Sasahara M, Imura J, Tokuyama K, Usui I, Nakagawa T, Fujisaka S, Yagi K, Tobe K. Astaxanthin stimulates mitochondrial biogenesis in insulin resistant muscle via activation of AMPK pathway. J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):241-258.
9. Kario K, Okada K, Murata M, Suzuki D, Yamagiwa K, Abe Y, Usui I, Tsuchiya N, Iwashita C, Harada N, Okawara Y, Ishibashi S, Hoshide S. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study. J Clin Hypertens (Greenwich) 2020 Sep; 22(9): 1585–1593.
10. Watanabe T. Ozawa A. Masuda S. Yoshino S. Ishida E. Kondo Y. Matsumoto S. Katano-Toki A. Horiguchi K. Nakajima Y. Yamada E. Tomaru T. Saito T. Ishii S. Shibusawa N. Okada S. Satoh T. Yamada M. Transcriptional Regulation of the Angpt18 Gene by Hepatocyte Nuclear Factor-1 in the Murine Liver. Sci Rep. 2020 Jun 19;10(1).

症例報告

1. Kishi H, Jojima T, Kogai T, Iijima T, Ohira E, Tanuma D, Konno S, Kato K, Kezuka A, Akimoto K, Sakumoto J, Hishinuma A, Tomaru T, Makita N, Usui I, Aso Y. A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation. Clin Case Rep. 2020 Aug 14;8(12):2619-2624.
2. Jojima T, Kogai T, Iijima T, Kato K, Sagara M, Kezuka A, Kase M, Sakurai S, Akimoto K, Sakumoto J, Namatame T, Ueki K, Hishinuma A, Kamai T, Usui I, Aso Y. Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. Eur J Endocrinol. 2020 Dec;183(6):K7-K12.
3. Shinohara Y, Iijima T, Sakurai S, Jojima T, Ohira E, Hayashi S, Usui I, Igawa K, Aso Y. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication. Clin Case Rep. 2020 Aug 30;8(10):2007-2012.

総論

1. 麻生 好正. 糖尿病と肥満度～全ての糖尿病患者がBMI22を目指すべきなのか～ 肥満度の適正と糖尿病薬物治療. 糖尿病63(7);433-436,2020.
2. 麻生 好正, 加瀬 正人. 糖尿病性自律神経障害の病態と対策　心血管自律神経障害を中心に. 月刊糖尿病 12(4);56-63,2020.
3. 麻生 好正, 加瀬 正人. 神経障害-その病期を再考する-　心血管自律神経障害の病期、診断. 糖尿病合併症 34(2);273-278,2020.
4. 麻生 好正. 糖尿病診療update-最新の診断と治療 糖尿病治療薬に関する最近の話題　インクレチン関連薬　DPP-4阻害薬. 日本臨床78(7);1128-1138,2020.
5. 麻生 好正.【糖尿病の合併症(腎・眼・心血管疾患)-新しい抗糖尿病薬で予後は変わるか】Consensus Report from ADA and EASD　Standards of medical care in Diabetes-2020より. カレントテラピー 38(4);367-374,2020.
6. 井上晃男、西野　節、八木　博、麻生好正.　糖尿病患者の冠動脈疾患をどう評価するか？　Heart View 2020;24; 584-591
7. 薄井勲：特集にあたって（巻頭言）。「糖尿病と肥満度」～全ての糖尿病患者がBMI22を目指すべきなのか～ 糖尿病63(7), 421, 2020
8. 薄井勲：特集　高血糖毒性と組織障害「４．癌」 糖尿病63(9), 601-604, 2020

研究論文

原著

1. Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, Iijima T, Maejima Y, Shimomura K, Usui I. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019 May;73(5):e13335.
2. Takikawa A, Usui I, Fujisaka S, Tsuneyama K, Okabe K, Nakagawa T, Nawaz A, Kado T, Jojima T, Aso Y, Hayakawa Y, Yagi K, Tobe K. Macrophage-specific hypoxia-inducible factor-1α deletion suppresses the development of liver tumors in high-fat diet-fed obese and diabetic mice. J Diabetes Investig. 2019 Nov;10(6):1411-1418.
3. Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int J Mol Sci. 2019 Oct 22;20(20). pii: E5237.
4. Hatano M, Inoue I, Kurihara S, Ono H, Matsuda M, Kakei M, Inukai T, Aso Y, Katayama S. Long-Term Efficacy and Safety of Add-On Therapy of Sitagliptin to a Very Small Dose of Glimepiride Versus a Small Dose of Glimepiride Over Eighteen Months. J Endocrinol Metab. 2019;9(6):171-179
5. Ando H, Horibata Y, Aoyama C, Shimizu H, Shinohara Y, Yamashita S, Sugimoto H. Side-chain Oxysterols Suppress the Transcription of CTP: Phosphoethanolamine Cytidylyltransferase and 3-hydroxy-3-methylglutaryl-CoA Reductase by Inhibiting the Interaction of p300 and NF-Y, and H3K27 Acetylation. J Steroid Biochem Mol Biol. 2019 Dec;195:105482.

症例報告

1. Kunii T, Iijima T, Jojima T, Shimizu M, Kase M, Sakurai S, Kogai T, Usui I, Aso Y. Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. J Med Case Rep. 2019 Apr 20;13(1):99.

総論

1. 麻生好正、加瀬正人.　糖尿病性自律神経障害Update～心血管自律神経障害を中心に～.　糖尿病合併症33; 254-259, 2019
2. 麻生好正、加瀬正人.　無自覚低血糖と自律神経障害.　内分泌・糖尿病・代謝内科 49; 256-263, 2019

著書

1. 麻生好正　今日の治療指針2019. 福井次矢、高木誠、小室一成　編.　11.代謝疾患.　糖尿病合併症,　pp732-736,　医学書院,　東京,　2019
2. 麻生好正　糖尿病治療のニューパラダイム　第4巻　糖尿病に合併する病態とその治療,　加来浩平,　宇都宮一典,　綿田裕孝,　松田昌文,　池上博司　編.　1章　急性合併症の病態とその治療.　糖尿病性ケトアシドーシス,　高血糖高浸透圧症候群,　乳酸アシドーシス,　pp17-27,　医薬ジャーナル,　大阪,　2019.3
3. 城島輝雄、菱沼昭：異所性甲状腺. 日本臨床　内分泌症候群（第3版）:pp558-561, 2018
4. 薄井勲，戸邉一之：第13章　糖尿病 ６．診断：病歴、診察、検査のポイント。 内分泌代謝科専門医研修ガイドブック 日本内分泌学会編, 609-611, 2018

原著

1. Takikawa A, Usui I, Fujisaka S, Tsuneyama K, Okabe K, Nakagawa T, Nawaz A, Kado T, Jojima T, Aso Y, Hayakawa Y, Yagi K, Tobe K.　Macrophage-specific hypoxia-inducible factor-1α deletion suppresses the development of liver tumors in high-fat diet-fed obese and diabetic mice. J Diabetes Investig. 2019 Mar 21. doi: 10.1111/jdi.13047. [Epub ahead of print]
2. Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, Iijima T, Maejima Y, Shimomura K, Usui I. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019 May;73(5):e13335. doi: 10.1111/ijcp.13335. Epub 2019 Apr 1.
3. Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2.
4. Iijima T, Niitani T, Tanaka S, Yanagi K, Jojima T, Suzuki K, Usui I, Aso Y. Concurrent variant type 3 autoimmune polyglandular syndrome and pulmonary arterial hypertension in a Japanese woman. Endocr J. 2018 Apr 26;65(4):493-498. doi: 10.1507/endocrj.EJ17-0465. Epub 2018 Feb 16.

総論

1. 加瀬 正人, 麻生 好正.　 糖尿病性神経障害～数値で糖尿病性神経障害を評価する～.　 5.　自律神経障害の評価.　糖尿病2018 年 61 巻 11 号 p. 754-756
2. 麻生好正. 特集　低血糖はなぜいけないか.　低血糖の定義と臨床症状－無自覚性低血糖の問題－.　糖尿病プラクティス 2018; 36:15-21 その他
3. 麻生好正.　Topics 最新の論文　肥満時の肝細胞由来DPP-4による脂肪組織炎症とインスリン抵抗性の促進.　Diabetes Strategy　2018; 8: 156-57

著書

1. 麻生好正.糖尿病合併症.古家大祐編.第1章　急性合併症の病態・診断・治療.高血糖高浸透圧症候群の病態・診断・治療，pp23-29，最新医学社，大阪，2017
2. 中島歩、薄井勲，戸邉一之：「インスリン抵抗性」を再考する．一歩進んだ糖尿病循環器病　綿田裕孝、大石充編、医学ジャーナル社: 53-61, 2017

総論

1. 麻生好正.　糖尿病神経障害と転倒リスク，糖尿病と骨粗鬆症の危うい関係.月刊糖尿病2017;6:54-61
2. 麻生好正.　糖尿病診療におけるweekly製剤（DPP-4阻害薬、GLP-1受容体作動薬）の有効な活用法.　糖尿病－健康長寿を実現する糖尿病の実地診療－.M.P. Medical Practice 34(9);1523-1530, 2017
3. 麻生好正.　自律神経障害、低血糖と心血管イベント.　糖尿病と心合併症2017~循環器専門医との連携を図る. Diabetes Frontier 28: 544-550, 2017
4. 麻生好正.　SGLT2阻害薬の最適な併用薬は?～配合錠を含めて～.　今，明かされるSGLT2阻害薬の多面的作用と適正使用.　月刊糖尿病2017;9:66-75
5. 麻生好正.　糖尿病神経障害患者のポリファーマシー.　ポリファーマシーの問題点と解決策.　カレントテラピー2018;36:174-180
6. 麻生好正.　糖尿病性神経障害Update.　臨床病理（日本臨牀検査医学会誌）66:306.-315, 2018
7. 薄井勲，戸邉一之：脂肪組織の炎症．実験医学 35(2): 85-91, 2017
8. 薄井勲，戸邉一之：SIRT1による脂肪組織の炎症およびインスリン抵抗性の制御．月刊糖尿病 9(3): 29-38, 2017
9. 薄井勲，戸邉一之：肥満症における脂肪組織マクロファージのHIF-1の重要性．内分泌・糖尿病・代謝内科 44(6): 449-454, 2017

原著

1. Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis. 2017 Apr 7;261:44-51.
2. Suzuki K, Aoki C, Kato K, Shimizu M, Sakurai S, Yanagi K, Kuroda H, Aso Y. Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study. Diabetes Ther. 2017 Apr;8(2):445-449　Jan 24. doi: 10.1007/s13300-017-0228-9. [Epub ahead of print]
3. Kato K, Suzuki K, Aoki C, Sagara M, Niitani T, Wakamatsu S, Yanagi K, Aso Y. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. Expert Opin Pharmacother. 2017 Apr 21:1-9.
4. Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, Yasu T, Harasawa H. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017 Jun 22. pii: S1262-3636(17)30107-6.
5. Matsumura M, Nakatani Y, Tanka S, Aoki C, Sagara M, Yanagi K, Suzuki K, Aso Y. Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Ther. 2017 J Aug;8(4):821-827.
6. Aso Y, Suzuki K, Chiba Y, Sato M, Fujita N, Takada Y, Murano S, Kuroda H. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial. Diabetes Res Clin Pract. 2017 Jun 15;130:237-243.
7. Maejima Y, Aoyama M, Sakamoto K, Jojima T, Aso Y, Takasu K, Takenosihita S, Shimomura K. Impact of sex, fat distribution and initial body weight on oxytocin's body weight regulation. Sci Rep. 2017 Aug 17;7(1):8599.
8. Iijima T, Kato K, Jojima T, Tomotsune T, Fukushima M, Suzuki K, Aso Y. Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. Diabetes Res Clin Pract. 2017 Nov;133:10-12.
9. 9. Suzuki K, Yanagi K, Shimizu M, Wakamatsu S, Niitani T, Hosonuma S, Sagara M, Aso Y. Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study. Endocr J. 2017;65(1):101-111

著書

1. 麻生好正．肥満症診療ガイドライン2016，肥満症に合併する疾患の治療，高血圧 pp 82-84，日本肥満学会編，ライフサイエンス出版，東京，2016
2. 麻生好正．糖尿病治療薬.クリニカルクエスチョン120.　Q31，Q32．寺内康夫，田島一樹，近藤義宣編、pp66-70，診断と治療社，東京，2016
3. 麻生好正.　 第3章　併存疾患や身体条件におけるmultimorbidityへの対処法，10.自律神経障害を有する糖尿病症例，糖尿病におけるmultimorbidity，pp227-236，松岡健平編，南山堂，東京，2017

原著

1. Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y. Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol. 2016 May 17;15(1):76.
2. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016 Jul 26;8:45.
3. Suzuki K, Sagara M, Aoki C, Tanaka S, Aso Y. Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes. Intern Med. 2017;56(1):17-21.
4. 麻生好正. 日本人肥満2型糖尿病患者におけるダパグリフロジンの効果.Progress in Medicine. 36: 1111-1120, 2016
5. Aoki C, Suzuki K, Kuroda H, Sagara M, Shimizu M, Kasai K, Aso Y. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci. 2017 Feb;79(1):9-16.

総論

1. 麻生好正．新時代の臨床糖尿病学（下）－より良い血糖管理をめざして－．XI．糖尿病合併症の病態・診断・治療．慢性合併症　糖尿病神経障害：糖尿病神経障害の疫学．日本臨牀 74 (S2): 217-222, 2016
2. 麻生好正. 糖尿病神経障害臨床の早期診断と薬物治療.　糖尿病性自律神経障害.　月刊糖尿病8 (8):54-61, 2016
3. 麻生好正.　DPP-4阻害薬の有効性～レスポンダー，ノンレスポンダー，2次無効～，DPP-4阻害薬を極める.月刊糖尿病2016;5:43-53

症例報告

1. Suzuki　K, Katsura D, Sagara M, Aoki C, Nishida M, Aso Y. Postprandial Reactive Hypoglycemia Treated with a Low-dose Alphaglucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction. Intern Med . 2016;55(8):949-53
2. Aoki C, Tanaka S, Suzuki K, Sagara M, Aso Y. Primary Adrenal Leiomyosarcoma in an Aged Japanese Woman: A Rare Case Report. J Clin Case Rep 2017 Jan; 7:3

著書

1. 麻生好正．いま知っておきたい経口糖尿病治療薬の疑問76.　Q30，Q31．寺内康夫編、pp118-123，南江堂，東京，2015
2. 麻生好正．8.内分泌疾患．インスリン受容体異常症．pp 1219-1221，今日の診断指針第7版，医学書院，東京，2015
3. 麻生好正．X. 糖尿病神経障害，3.糖尿病筋委縮症，pp215-17．糖尿病最新の治療2016-2018，羽田勝計・門脇孝・荒木栄一編，南江堂，東京，2016
4. 麻生好正．I．糖尿病の病態をどう捉える．Q18. 糖尿病神経障害と自律神経障害、特に交感神経との関係について教えて下さい．Pp64-67．心血管事故を予防するための糖尿病治療戦略，伊藤　浩，綿田裕孝編，文光堂，東京，2016

原著

1. Nohara A, Maejima Y, Shimomura K, Kumamoto K, Takahashi M, Akuzawa M, Negishi M, Ishiyama N, Nagano N, Aso Y, Takenoshita S, Shimomura Y. Self-awareness of fast eating and its impact on diagnostic components of metabolic syndrome among middle-aged Japanese males and females. Endocr Regul. 2015;49(2):91-6.
2. Akiyama Y, Morita-Ohkubo T, Oshitani N, Ohno Y, Aso Y, Inukai T, Kakei M, Kawakami M, Awata T, Katayama S, and Matsuda M: Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study. Diabetology International 10.1007/s13340-015-0207-1
3. Aso Y, Jojima T, Iijima T, Suzuki K, Terasawa T, Fukushima M, Momobayashi M, Hara K, Takebayashi K, Kasai K, Inukai T. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+cells in patients with type 2 diabetes. Endocrine2015 Dec;50(3):659-64.
4. Aso Y, Fukushima M, Sagara M, Jojima T, Iijima T, Suzuki K, Momobayashi M, Kasai K, Inukai T. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Res Clin Pract 2015 Dec;110(3):250-6
5. 加藤嘉奈子, 鈴木國弘, 相良匡昭, 青木千枝, 城島輝雄, 麻生好正．高齢者2型糖尿病患者における認知機能調査とその関連因子について．Dokkyo J Med Sci 43: 67-71, 2016

レター

1. Nakatani Y, Kawabe A, Matsumura M, Aso Y, Yasu T, Banba N, Nakamoto T. Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabetes Care. 2016 Feb;39(2):e22-3.

症例報告

1. Shimizu M, Suzuki K, Tsuchida K, Kojima M, Hiraishi H, Aso Y. Insulinoma in a patient with chronic renal failure due to type 2 diabetes mellitus treated effectively with diazoxide. Intern Med. 2015;54(6):621-5
2. 相良匡昭, 城島輝雄, 加藤嘉奈子, 清水昌紀, 西田 舞, 加瀬正人, 櫻井慎太郎, 友常孝則, 田中精一, 青木千枝, 柳　一徳, 桂　大輔, 鈴木國弘, 飯嶋寿江, 樋口芙未, 川本俊樹, 小島久男, 小島　勝, 麻生好正．高熱と慢性貧血を契機に発見されたIL-6産生下垂体腺腫の1例．日本内分泌学会雑誌2015;91:S16-19
3. 飯嶋寿江, 加瀬正人, 相良匡昭, 加藤嘉奈子, 清水昌紀, 西田 舞, 友常孝則, 田中精一, 青木千枝, 城島輝雄, 鈴木國弘, 黒田久元, 麻生　好正．自殺企図にてインスリンデグルデクとインスリンリスプロを大量に皮下注射した１型糖尿病の１例．糖尿病 2015; 58: 707-714

総論

1. 麻生好正．新時代の2型糖尿病治療～中心的薬剤としてのDPP-4阻害薬～．東京都医師会雑誌 68 (6): 33-40, 2015
2. 麻生好正．2型糖尿病患者における血清可溶性DPP-4/CD26値の臨床的意義．アニムス 84: 17-21, 2015
3. 友常孝則，麻生好正．糖尿病性自律神経障害の診断と治療．Diabetes Frontier 26: 472-477, 2015
4. 麻生好正．最新エビデンスに学ぶ、効果が上がる肥満食事療法の実践．2．肥満に起因する各種疾患の診療－高血圧．臨床栄養（臨時増刊）127:422-425, 2015
5. 麻生好正．インクレチン関連薬と心不全－beneficialなのかadverseなのか?－．循環器診療23: 25-29, 2015
6. 麻生好正．糖尿病治療薬Update．Overview　血糖コントロールの目標設定．medicina 53: 1821-1480, 2016

学会

国際学会

Aso Y, Sagara M, Jojima T, Iijima T, Suzuki K, Inukai T. Sitagliptin, a DPP-4 Inhibitor, Alters the Number and Proportion of the Subsets of Circulating CD4+ T Cells in Patients with Type 2 Diabetes. 75th Scientific sessions, American Diabetes Association, Boston, USA, 2015.6

著書

麻生好正．糖尿病専門医研修ガイドブック改訂第6版：第11章　合併症．2 慢性合併症の病態，診断と治療．5 神経障害．日本糖尿病学会編、pp295-299、診断と治療社、東京、2014年5月

原著

1. Terasawa T, Aso Y, Omori K, Fukushima M, Momobayashi A, Inukai T. Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes. Transl Res. 2015 Feb;165(2):336-45.
2. Suzuki K, Tanaka S, Aoki C, Kato K, Jojima T, Aso Y. Greater efficacy and improved endothelial dysfunction in untreated type 2 diabetes with liraglutide versus sitagliptin. Dokkyo J Med Sci 41: 211-220, 2014
3. Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, Aso Y. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther. 2014 Dec;16(12):840-5
4. Domeki N, Matsumura M, Monden T, Nakatani Y, Aso Y. A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2014 Dec;5(2):403-13.
5. Naruse R, Hori K, Terasawa T, Hara K, Suetsugu M, Takebayashi K, Morita K, Aso Y, Inukai T. Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients. Obes Res Clin Pract. 2015 Jan-Feb;9(1):67-74
6. Suzuki K, Tanaka S, Yanagi K, Iijima T, Niitani M, Coletta C, Szabo C, Aso Y. Epalrestat induces cell proliferation and migration in endothelial cells via mTOR activation through PI3/Akt signaling. Diabetology International 5: 105-111, 2014
7. Hara K, Aso Y, Komatsu T, Nakamachi T, Sakai Y, Takayanagi K, Kasai K, Inukai T. Liraglutide increases the 24-hour heart rate by diminishing cardiac parasympathetic activity in patients with type 2 diabetes: Power spectral analysis of heart rate variability on 24-hour Holter ECG recordings. Diabetology International 6: 26-32, 2015
8. 麻生好正，原　直，大越恭二，大和田一博，生井一之，犬飼浩一，角　誠二郎，犬飼敏彦．降圧不十分な高血圧患者に対するロサルタン/ヒドロクロロチアジド配合剤の降圧効果と代謝系に関する検討: ELUCIDATE研究中間報告．Progress in Medicine. 34: 1103-1111, 2014
9. 松村美穂，中谷祐己，百目木希美，柳　一徳，池田志織，伴場信之，森山俊男，麻生好正．糖尿病患者における自動車運転中の低血糖発作の実態～低血糖発作による交通事故低減への啓発～．糖尿病57: 329-336, 2014

症例報告

1. 城島輝雄, 加藤嘉奈子, 相良匡昭,清水昌紀, 菊池朋子, 西田 舞, 加瀬正人, 友常孝則, 田中精一, 青木千枝, 柳　一徳, 桂　大輔, 鈴木國弘, 飯嶋寿江, 田口裕久, 川越宜明, 笠井貴久男, 麻生好正．バセドウ病加療中の無顆粒球症を契機に発見されたIgG4関連甲状腺炎の1例. 日本内分泌学会雑誌2014;90:S30-32

総論

1. 麻生好正．糖尿病神経障害の最近の進歩．自律神経障害．糖尿病 57: 598-601, 2014
2. 飯島寿江，麻生好正．糖尿病患者を診る．治療と兼科のポイント．向精神薬の血糖コントロールへの影響．medicina 51: 1476-1480, 2014